NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avectas

Avectas

Private
DublinHealthcare & Life Scienceshttps://www.avectas.com/

Last Round

Grant

Apr 22, 2021

Total Funding Raised

$31.28M

Company Overview

Avectas is a biotechnology company that has developed a cell engineering platform intended to enable the ex vivo manufacture of gene-modified cell therapy products.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Non-AI

Keywords

cell engineeringnon-viral deliverycell therapy manufacturingcell and gene therapytransfection technologycell permeabilizationGMP manufacturingbioprocess technologyautomated manufacturingCAR-Telectroporation alternativeCRISPR deliverymRNA deliveryCDMOcontract development and manufacturing organizationallogeneic cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avectas Comparables

Compare Avectas with similar companies based on industry and business-model similarity.

Avectas comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Indee Labs
85%
CellFE
85%
Kytopen
84%

Avectas Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 22, 2021
Series CApr 16, 2020
VC RoundApr 9, 2019
GrantMar 20, 2018

Key People

Founding team and executive leadership

Michael Maguire

Chief Executive Officer

Executive Team

Ann Brady

Chief Business Officer, Board Member

Executive Team

Avectas Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 23, 2026

    Monthly visitors increased 506% MoM.

  • Jan 6, 2026

    Monthly visitors increased 174% MoM.

Avectas Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avectas Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avectas's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range31
Year Founded2011
Last FundingApr 22, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.